JP2018518518A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518518A5
JP2018518518A5 JP2017567146A JP2017567146A JP2018518518A5 JP 2018518518 A5 JP2018518518 A5 JP 2018518518A5 JP 2017567146 A JP2017567146 A JP 2017567146A JP 2017567146 A JP2017567146 A JP 2017567146A JP 2018518518 A5 JP2018518518 A5 JP 2018518518A5
Authority
JP
Japan
Prior art keywords
group
alkyl
pharmaceutical composition
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017567146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518518A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039365 external-priority patent/WO2016210330A1/en
Publication of JP2018518518A publication Critical patent/JP2018518518A/ja
Publication of JP2018518518A5 publication Critical patent/JP2018518518A5/ja
Ceased legal-status Critical Current

Links

JP2017567146A 2015-06-26 2016-06-24 グルコース取り込み阻害剤 Ceased JP2018518518A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185223P 2015-06-26 2015-06-26
US62/185,223 2015-06-26
PCT/US2016/039365 WO2016210330A1 (en) 2015-06-26 2016-06-24 Glucose uptake inhibitors

Publications (2)

Publication Number Publication Date
JP2018518518A JP2018518518A (ja) 2018-07-12
JP2018518518A5 true JP2018518518A5 (enExample) 2019-07-25

Family

ID=57586425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567146A Ceased JP2018518518A (ja) 2015-06-26 2016-06-24 グルコース取り込み阻害剤

Country Status (8)

Country Link
US (2) US10273248B2 (enExample)
EP (1) EP3313825A4 (enExample)
JP (1) JP2018518518A (enExample)
CN (1) CN108349910A (enExample)
CA (1) CA3028355A1 (enExample)
EA (1) EA201890153A1 (enExample)
HK (1) HK1254835A1 (enExample)
WO (1) WO2016210330A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3573992B1 (en) * 2017-01-26 2022-04-13 Youla S. Tsantrizos Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
US11071735B2 (en) 2017-04-28 2021-07-27 Kadmon Corporation, Llc Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CN110573501B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
AU2018294054B2 (en) 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
US10689386B2 (en) 2018-03-07 2020-06-23 Duquesne University Of The Holy Spirit Pyrazolo[4,3-d]pyrimidines as antitumor agents
WO2020005935A1 (en) * 2018-06-25 2020-01-02 Kadmon Corporation, Llc Glucose uptake inhibitors
WO2021095032A1 (en) * 2019-11-13 2021-05-20 Metabomed Ltd Glucose uptake inhibitors and uses thereof
BR112022010254A2 (pt) * 2019-12-02 2022-09-06 Shanghai Yingli Pharm Co Ltd Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
AU2021309876B2 (en) * 2020-07-14 2024-06-27 Wuhan Ll Science And Technology Development Co., Ltd. Rock inhibitor, and preparation method therefor and use thereof
CN112479913A (zh) * 2020-11-19 2021-03-12 安徽修一制药有限公司 一种n,n-二乙基氯代乙酰胺的制备方法
CN112741828B (zh) * 2021-01-08 2022-04-26 武汉大学 药物联用物及其制备方法和用途
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
CN117820328A (zh) * 2023-11-21 2024-04-05 苏州楚凯药业有限公司 一种2,4-二氯-6,7-二氢呋喃并[3,2-d]嘧啶的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Rho−キナーゼ阻害剤
WO2009079412A2 (en) * 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
CN102791697A (zh) * 2009-10-12 2012-11-21 瑞科西有限公司 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
CN102901456B (zh) 2012-09-12 2015-10-28 深圳深蓝精机有限公司 检测装置及检测圆轴的外径、跳动值、真圆度的方法
EP2903618B1 (en) * 2012-10-05 2022-06-01 Kadmon Corporation, LLC Rho kinase inhibitors
US10729691B2 (en) * 2015-06-26 2020-08-04 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors

Similar Documents

Publication Publication Date Title
JP2016515561A5 (enExample)
JP2014521688A5 (enExample)
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2019524883A5 (enExample)
JP2019500387A5 (enExample)
JP2017515901A5 (enExample)
JP2016521273A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2016530259A5 (enExample)
JP2017537940A5 (enExample)
JP2015509983A5 (enExample)
JP2015532295A5 (enExample)
JP2015523383A5 (enExample)
JP2016515560A5 (enExample)
JP2016517417A5 (enExample)
JP2015520769A5 (enExample)
JP2016506960A5 (enExample)
JP2014508804A5 (enExample)
JP2014500265A5 (enExample)
JP2012519691A5 (enExample)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
EA202192512A1 (ru) Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv
JP2016531126A5 (enExample)
JP2020500866A5 (enExample)